New Group of Potential Diabetes Drugs With Fewer Side Effects Can Reprogram Insulin-Resistant Cells to Be Healthier

Scientists at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology have developed a promising new group of experimental diabetes drugs that could significantly improve how insulin-resistant cells function, while avoiding many of the dangerous side effects linked to older medications. The research focuses on a long-studied but notoriously difficult drug target and combines advanced computer modeling, structural biology, and cell-based testing to design compounds that fine-tune cellular behavior rather than forcing it into extreme responses.

Type 2 diabetes affects an estimated 36 million people in the United States, and the numbers continue to rise worldwide. The disease develops when the body’s cells stop responding properly to insulin, the hormone that allows glucose to enter cells and be used for energy. Over time, insulin resistance leads to chronically high blood sugar levels, increasing the risk of heart disease, nerve damage, kidney disease, vision problems, and cognitive decline. About one-third of people with type 2 diabetes also suffer from chronic kidney disease, which severely limits the medications they can safely use.

This new research, led by Patrick Griffin, Ph.D., scientific director of the Wertheim UF Scripps Institute, along with graduate researcher Kuang-Ting Kuo, offers a potential path forward for patients who currently lack safe and effective treatment options. Their findings were published in Nature Communications, one of the leading journals for high-impact biomedical research.

Targeting PPAR Gamma, a Powerful but Tricky Protein

At the center of the study is PPAR gamma (peroxisome proliferator-activated receptor gamma), a protein that plays a major role in fat cell biology, insulin sensitivity, and metabolic regulation. PPAR gamma belongs to a class of proteins known as nuclear receptors, which bind directly to DNA and control whether certain genes are switched on or off. Because of this, PPAR gamma influences not just diabetes, but also inflammation, obesity, cardiovascular disease, osteoporosis, and even certain cancers.

For decades, PPAR gamma has been an attractive drug target for improving insulin sensitivity. Drugs known as glitazones, including Actos (pioglitazone) and Avandia (rosiglitazone), work by strongly activating this protein. While effective at lowering blood sugar, these drugs have been linked to serious side effects such as fluid retention, bone fractures, heart failure, and increased cancer risk. Due to these risks, the U.S. Food and Drug Administration requires a boxed warning on all glitazone medications.

The challenge has never been whether PPAR gamma is useful, but how to control it safely. According to the researchers, fully turning the protein “on” or “off” creates problems. What patients need instead is a way to subtly reprogram how the protein behaves.

Designing Smarter Compounds With Fewer Risks

Rather than developing drugs that strongly activate PPAR gamma, the UF Scripps team designed non-covalent inverse agonists that reshape how the protein moves and interacts with other molecules. These compounds do not permanently bind to PPAR gamma. Instead, they influence its structure in a way that restores insulin sensitivity without triggering harmful downstream effects.

To accomplish this, the researchers used a powerful combination of techniques. First, they conducted biochemical testing to measure how different compounds altered PPAR gamma activity. They then applied hydrogen-deuterium exchange mass spectrometry (HDX-MS), a method that reveals subtle changes in protein shape and flexibility. This allowed the team to see exactly how each compound affected the structure of PPAR gamma at a molecular level.

The most computationally intensive part of the work involved molecular dynamics simulations performed on HiPerGator, the University of Florida’s supercomputer. HiPerGator allowed researchers to simulate how PPAR gamma moves over time when bound to each compound. A single 100-nanosecond simulation took about six hours to complete. With 26 compounds and three independent simulations per compound, the total computing time approached 20 days, even on one of the fastest academic supercomputers available.

After narrowing down the most promising candidates, the team tested them in mouse and human fat cells. These experiments showed that the compounds could improve insulin sensitivity and push insulin-resistant cells toward a healthier metabolic state.

Why Current Diabetes Drugs Are Not Enough

The most commonly prescribed front-line drug for type 2 diabetes, metformin, helps lower blood sugar but does not significantly improve insulin sensitivity in many high-risk patients. For individuals with chronic kidney disease, treatment options become even more limited, as several newer diabetes drugs can worsen kidney function or carry additional risks.

This gap in treatment options is what makes the new study especially important. By precisely controlling PPAR gamma activity, the researchers aim to create medications that are effective without being dangerous, particularly for patients who cannot tolerate existing therapies.

The Griffin laboratory has been working on alternative PPAR gamma compounds for more than 15 years, and this study represents a major step forward in predicting therapeutic outcomes before drugs reach later stages of development. The researchers believe their approach could reduce costly failures and safety issues during clinical trials.

A Transferable Framework for Drug Discovery

One of the most valuable outcomes of this research is not just the compounds themselves, but the methodology used to create them. By combining computer modeling, structural measurements, and cell-based testing, the team developed a framework that can be applied to other complex drug targets beyond diabetes.

Proteins like PPAR gamma are difficult to study because they are flexible and interact with many different partners inside the cell. Traditional drug discovery methods often fail to capture this complexity. The integrated approach used in this study allows scientists to see how structure, movement, and biological activity are connected, leading to smarter drug design.

What Comes Next for These Compounds

The research is still in the preclinical stage, meaning the compounds have not yet been tested in animals or humans beyond basic cell studies. The next phase will involve examining how the compounds behave in more complex biological systems, including how they affect different tissues throughout the body.

Future studies will also explore how downstream signaling molecules interact with the PPAR gamma-targeting compounds. Understanding these interactions will be crucial for predicting long-term safety and effectiveness.

While it will take time before any of these compounds reach clinical trials, the researchers believe the work represents a meaningful step toward safer diabetes treatments. For patients with limited options, especially those with kidney disease, the ability to reprogram insulin-resistant cells without severe side effects could be life-changing.

Understanding PPAR Gamma and Insulin Sensitivity

PPAR gamma plays a central role in how fat cells store lipids and respond to insulin. When regulated correctly, it helps maintain glucose balance and metabolic health. When overstimulated, however, it can cause excessive fat accumulation, fluid retention, and cardiovascular stress. This delicate balance explains why drug design around PPAR gamma has been so difficult and why subtle modulation is key.

The new compounds developed at UF Scripps aim to strike that balance, offering a way to harness the benefits of PPAR gamma while minimizing its risks. If successful in future testing, this strategy could influence how scientists approach not only diabetes drugs, but treatments for many diseases involving complex signaling proteins.

Research paper: https://doi.org/10.1038/s41467-025-67608-5